Loading patent…
AssigneesInstitut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Universite Paris-Saclay
InventorsLaurence Zitvogel, Lisa Derosa
Estimating the term…
The invention pertains to the use of bacteria selected amongst Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum for inducing immunostimulation in a patient in combination with an anti-cancer immunotherapy with an immune check-point inhibitor (ICI) and/or a tyrosine kinase inhibitor (TKI). The invention also relates to methods for assessing the probability that N a patient respond to a treatment with an ICI and/or a TKI, based on measuring the relative abundances of immunotolerant bacterial species (Clostridium hathewayi, Clostridium clostridioforme and Clostridium boltae) and/or immunostimulatory bacterial species CN (Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum) in the patient's gut microbiota.
A method for treating a patient with a renal cell cancer comprising administering a composition enriched for bacteria selected from the group consisting of Dorea longicatena and Eubacterium siraeum in combination with an immune checkpoint inhibitor (ICI)-based therapy or a tyrosine kinase inhibitor (TKI)-based therapy, wherein said bacterial administration results in a relative abundance of >0.855% for D. longicatena or generates a relative abundance of >1.11% for E. siraeum in a feces sample from the patient and induces immunostimulation in the cancer patient and improves efficacy of the (ICI)-based or (TKI)-based therapy.
Dependencies are inferred from the claim text.